Cerevel Therapeutics Holdings, Inc. was an American biotechnology and pharmaceuticals company based in Cambridge, Massachusetts, focused on the development of novel therapies for mental and neurological illnesses. From Wikipedia
AbbVie's emraclidine failed to meet key endpoints in Phase 2 trials, impacting its $8.7 billion acquisition of Cerevel Therapeutics.
